ALLUVI: A DETAILED EXAMINATION INTO THE DRUG'S POTENTIAL

Alluvi, previously BI 4744, offers a notable breakthrough in weight control treatment. This dual activator targeting both GLP-1 and GIP targets demonstrates remarkable effectiveness in patient assessments, possibly exceeding current GLP-1 site activators. Early information show meaningful {weight